Previous 10 | Next 10 |
Achieve Life Sciences Announces Pricing of $15 Million Public Offering SEATTLE and VANCOUVER, B.C. , Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerci...
Achieve Life Sciences (ACHV) to offer 1.5M common shares in a public offering, underwriters have an option to purchase up to an additional 225k shares.Price, other terms are yet to be decided.Shares are down 4.4% in premarket For further details see: Achieve Life Sciences...
Achieve Life Sciences, Inc. (ACHV) Q3 2020 Earnings Conference Call November 12, 2020 16:30 ET Company Participants Jaime Xinos - Executive Vice President, Commercial John Bencich - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jerry Wan - Principal Accounting Off...
Achieve Life Sciences (ACHV): Q3 GAAP EPS of -$1.14 beats by $0.17.Cash, cash equivalents, and restricted cash of $22.4MPress Release For further details see: Achieve Life Sciences EPS beats by $0.17
Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update Canada NewsWire SEATTLE and VANCOUVER, BC, Nov. 12, 2020 SEATTLE and VANCOUVER, BC , Nov. 12, 2020 /CNW/ -- Achieve Life Sciences, Inc. (N...
Achieve Life Sciences to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020 PR Newswire SEATTLE and VANCOUVER, BC, Oct. 29, 2020 SEATTLE and VANCOUVER, BC , Oct. 29, 2020 /PRNewswire/ -- Achieve Life Sc...
Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020 PR Newswire SEATTLE and VANCOUVER, BC, Oct. 27, 2020 SEATTLE and VANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (NASDAQ:...
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / October 8, 2020 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it...
Achieve Life Sciences (ACHV) has initiated Phase 3 ORCA-2 clinical trial, evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the U.S.The participants will be randomized to one of three study arms of cyt...
Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo Phase 3 ORCA-2 Trial to Enroll 750 Smokers Acro...
News, Short Squeeze, Breakout and More Instantly...
Achieve Life Sciences Inc. Company Name:
ACHV Stock Symbol:
NASDAQ Market:
Achieve Life Sciences Inc. Website:
2024-05-17 13:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical...
SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced data ...